MURRAY HILL, N.J. -- C.R. Bard, Inc. announces publication of a prospective, observational study which compares clinical and economic outcomes between the use of the Bard® StatLock® catheter stabilization device and the use of tape to safely stabilize peripheral I.V. catheters. The StatLock device is marketed by Bard Medical Division located in Covington, Ga.
The study, authored by Gregory Schears, MD, an anesthesiologist and pediatric intensivist based in Rochester, Minn., was part of the clinical evidence considered by the Infusion Nurses Society (INS), publishers of the Journal of Infusion Nursing, prior to the Society issuing its new national Infusion Nursing Standards of Practice* recommending that whenever possible, using a manufactured catheter stabilization devices is preferred. The study was published in the July/August issue of the Journal of Infusion Nursing and encompassed 10,164 patients in product trials conducted in 83 different hospitals.
Compared to the habit-based method of using tape to stabilize IV catheters, the Schears study concluded that the StatLock device showed statistical significance in:
-- reducing the rate of phlebitis complications by 80 percent
-- lowering the rate of overall complications related to the patients IV therapy by 67 percent
-- reducing unscheduled restarts by 76 percent
The study also suggests meaningful potential cost savings from using the device. In one hospital, for example, the studys cost-benefit analysis revealed that the use of the StatLock device yielded an overall annual savings of $277,085 from materials, nursing time and treatment of avoidable complications.
In analyzing the study data, Schears noted the consistency of the data from hospital to hospital. This is certainly the largest study of its kind, he noted, and it supports the idea that a catheter stabilization device can be beneficial for patients who need peripheral IVs and for the hospitals that use the device.
* While INS does not endorse or recommend specific products, as of today, the StatLock device is the only evidence-based catheter stabilization device that meets the new national standards.
Source: C. R. Bard, Inc.          Â
Â
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.